Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03120130
Other study ID # PGUQ002
Secondary ID
Status Suspended
Phase Phase 1
First received
Last updated
Start date February 15, 2021
Est. completion date May 22, 2022

Study information

Verified date June 2019
Source União Química Farmacêutica Nacional S/A
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Amblyomin-X is an inhibitor of Factor Xa that also acts as an apoptotic agent for tumor cells. In the case of in vitro assays, Amblyomin-X induces tumor cells to death and does not affect the viability of normal cells. When in vivo assays were performed on mice bearing tumors, treatment with Amblyomin-X caused a significant reduction in tumor mass and number of metastases.


Description:

This trial will be the first clinical study in humans with the product, which until then has been studied only in experimental models. Given the current epidemiological impact of cancer and the need to improve its systemic treatment, making it available to a larger portion of the Brazilian population, it is proposed to conduct the first Amblyomin-X study in cancer patients, more specifically those with advanced solid tumors For which there is no contraindicated or inaccessible therapeutic option established as the standard at the time of inclusion in the study.


Recruitment information / eligibility

Status Suspended
Enrollment 24
Est. completion date May 22, 2022
Est. primary completion date August 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Eligible patients must sign the Free and Informed Consent Term (TCLE),

- be between 18 and 75 years of age,

- present a solid tumor proven by anatomopathological examination at an advanced or metastatic stage and refractory to conventional treatment or without current indication or access to conventional treatment ,

- have a life expectancy of at least 12 weeks.

- presence of measurable disease according to Response Response Criteria in Solid Tumors (RECIST, version 1.1),

- medullary, renal and hepatic functions within acceptable limits (defined in protocol),

- end of the previous antineoplastic treatment at least 4 weeks (since the last dose of any antineoplastic medication, radiotherapy, or surgical procedure).

Exclusion Criteria:

- The presence of previously non-irradiated brain metastasis;

- Prediction of the use of radiotherapy, surgery, systemic antineoplastic treatment, or any other form of treatment for cancer after inclusion in the study;

- Prediction of corticosteroid use, hematopoietic growth factors or inhibitors of bone resorption during the first course of treatment (4 weeks);

- Regular use of anticoagulants or known previous coagulation disorder;

- Severe comorbidity (at the discretion of the researcher);

- Gestational, lactating, pregnant women, or who have not been surgically infertile or menopausal for at least 12 months;

- Men and women who refuse to use an adequate contraceptive method during the study period;

- Participation of another clinical study in the last 12 months (unless justified by the investigator);

- Or inability to comply with study requirements and procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Amblyomin-X
Intravenous drug administration, with different doses in each cohort

Locations

Country Name City State
Brazil União Química Farmacêutica Nacional Sao Paulo SP

Sponsors (2)

Lead Sponsor Collaborator
União Química Farmacêutica Nacional S/A Buranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda ME

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary grade 4 or non-haematological grade 3 haematological toxicity according to the CTCAE (version 4) Presence of grade 4 or non-haematological grade 3 haematological toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4) 2 weeks
Secondary maximum tolerated dose (MTD) and the recommended dose for phase II This will be based on dose-limiting toxicity of the previous cohort 2 weeks
Secondary Adverse Events haematological toxicity 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Completed NCT01197170 - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Phase 1
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03994601 - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01393990 - A Study of LY2228820 in Participants With Advanced Cancer Phase 1
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Active, not recruiting NCT04121676 - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer Phase 1
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03674567 - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04823377 - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. N/A
Completed NCT02778126 - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Phase 1
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Completed NCT02245204 - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers Phase 1
Completed NCT01583777 - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer Phase 1
Completed NCT01901237 - Yoga for Adolescent and Young Adult Non-Curative Cancer Patients N/A